CynergisTek Signs Six-Figure Extension Contract with Nationally Ranked Hospital

A nationally recognized hospital, specializing in women and children care, expands its contract with CynergisTek to add additional remediation support services

CynergisTek (NYSE American: CTEK), leading cybersecurity, privacy, compliance, and IT audit firm helping organizations in highly regulated industries navigate emerging security and privacy issues, recently announced one of the top obstetric and pediatric hospitals in the country that is also part of a prestigious academic medical center has signed a six-figure extension contract for professional service hours. The hospital continues to invest in CynergisTek’s virtual staffing and remediation services, adding over one thousand more hours of support throughout the next year.

“I have no doubt that this will continue to be a strong partnership with this client, and we are pleased to expand on offering our custom staffing remediation services,” said Mac McMillan, President, and CEO of CynergisTek. “The recent contract supports CynergisTek’s strategy to expand client retention, develop stronger relationships, and help protect the healthcare industry as a whole. Our job is to help identify gaps in your programs and provide guidance on how to remediate those gaps because simply knowing they are there isn’t enough.”

The agreement is an extension to the original contract that began in 2020 and enables the client to continue to leverage the value of CynergisTek’s solutions to optimize virtual staffing resources and enhance the client’s security programs. As healthcare continues to be a target of cyber-related incidents, hospitals need to take necessary steps to not only identify cyber risks, but follow through with prioritized remediation efforts to protect patient data, and avoid obstructing patient care. CynergisTek’s Information Security Remediation Services provide healthcare organizations with subject matter expertise from seasoned professionals who offer guidance and suggestions based on industry best practices, and the NIST privacy/security framework, to help address and remediate gaps in privacy, cybersecurity, compliance, and/or IT Audit programs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”